Primary Bilateral Macronodular Adrenal Hyperplasia: A Case Series from a Tertiary Hospital
Endocrinology Insights · 2024
DOI: 10.1159/000541914 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology Insights, 2024. Verfasst von Juliana Gonçalves und 8 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a rare etiology of Cushing’s syndrome characterized by the presence of multiple adrenal macronodules and variable levels of cortisol excess. Its pathogenesis is complex, involving mechanisms such as aberrant hormone receptors, adrenal paracrine ACTH production, and genetic germline pathogenic variants. However, management is not well established.
Methods
This was a retrospective, observational study. We evaluated patients with PBMAH at our tertiary center. We aimed to describe the clinical, hormonal, and radiological characteristics; treatment approaches; and outcomes.
Results
Twenty patients were included in this study. Patients had a mean age at diagnosis of PBMAH of 56.1 ± 11.1 years, and 10 patients (50.0%) were females. Most cases were initially investigated for adrenal incidentalomas. Median 8:00 a.m. serum cortisol after 1 mg dexamethasone overnight suppression test was 223.5 (73.1–698.6) nmol/L (8.11 [2.65–25.3] µg/dL), late-night salivary cortisol was 1.48 (0.765–3.21) times the upper limit of normal (ULN), and 24 h-UFC was 1.61 (0.42–3.64) times the ULN. One patient presented with the co-secretion of cortisol and aldosterone. Mean total adrenal size was 98.5 ± 25.6 mm, and the largest nodule size was 32.1 ± 9.09 mm. In six (31.6%) patients, the largest nodule had an attenuation higher than 10 HU. Germline pathogenic variants in ARMC5 were found in four (50.0%) of the eight tested patients who underwent genetic testing. Treatment strategies varied, with unilateral adrenalectomy often successfully controlling hypercortisolism in five (83.3%) of 6 patients with modest excess cortisol secretion. For mild autonomous cortisol secretion, active surveillance of comorbidities and appropriate treatment were not associated with progression of cortisol secretion after a median follow-up of 34.0 (10.5–83.0) months.
Conclusion
This study underscores the need for personalized management strategies and identifies areas for future research to optimize the care of patients with PBMAH.
Zitieren
APA
Gonçalves, J., Moreno, T., Ferreira, H. U., Menino, J., Dourado, J., Silva, D. F., Borges-Canha, M., Pedro, J., & Queirós, J. (2024). Primary Bilateral Macronodular Adrenal Hyperplasia: A Case Series from a Tertiary Hospital. Endocrinology Insights. https://doi.org/10.1159/000541914
Vancouver
Gonçalves J, Moreno T, Ferreira HU, Menino J, Dourado J, Silva DF, et al. Primary Bilateral Macronodular Adrenal Hyperplasia: A Case Series from a Tertiary Hospital. Endocrinology Insights. 2024. doi:10.1159/000541914
BibTeX
@article{Gonalves2024,
author = {Gonçalves, Juliana and Moreno, Telma and Ferreira, Helena Urbano and Menino, João and Dourado, João and Silva, Diana Festas and Borges-Canha, Marta and Pedro, Jorge and Queirós, Joana},
title = {Primary Bilateral Macronodular Adrenal Hyperplasia: A Case Series from a Tertiary Hospital},
journal = {Endocrinology Insights},
year = {2024},
doi = {10.1159/000541914}
}
EUVIMED